Drug Delivery
12 Results were found on Technologies
Sub Category Name
Novel Specific Disease-Modifying PERK Activator for Huntington’s Disease
The need: There is no efficient therapy at present for Huntington’s disease (HD) nor for any other neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. No disease-modifying approaches exist. • Gene therapy-based clinical trials have failed so far, highlighting the need for other approaches. These include the recent interruption of antisense oligonucleotide clinical trials for HD. Background […] Read More >
Improved Calcitonin-based Therapeutics
TechnologyThe aggregation site on human calcitonin has been identified, paving the way for development of specific inhibitors of calcitonin amyloid fibril formation. Such inhibitors will enable development of improved calcitonin therapeutics as well as greatly facilitate in vitro calcitonin manipulations. The NeedThe therapeutic use of human calcitonin is severely limited by its tendency to associate […] Read More >
